Preferred Label : Cipaglucosidase Alfa;
UNII : 4SED7F4BSG;
CAS number : 2359727-71-0;
NCI Metathesaurus CUI : CL1412297;
Origin ID : C175059;
UMLS CUI : C5421138;
Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
https://www.ema.europa.eu/en/medicines/human/EPAR/pombiliti
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Cipaglucosidase Alfa
Cipaglucosidase Alfa
cipaglucosidase alfa
enzyme replacement therapy
glycogen storage disease type ii
Glycogen storage disease type II late onset (disorder)
drug therapy, combination
miglustat
infusions, intravenous
pregnancy
breast feeding
drug evaluation, preclinical
adult
---
https://ansm.sante.fr/tableau-acces-derogatoire/atb200-cipaglucosidase-alfa
2023
false
false
false
France
French
drug information
Cipaglucosidase Alfa
cipaglucosidase alfa
---
https://www.has-sante.fr/jcms/p_3470276/fr/pombiliti-cipaglucosidase-alfa-/-opfolda-miglustat-forme-tardive-de-la-maladie-de-pompe
2023
false
false
false
France
Glycogen storage disease type II late onset (disorder)
treatment outcome
insurance, health, reimbursement
drug therapy, combination
enzyme replacement therapy
adult
cipaglucosidase alfa
infusions, intravenous
administration, oral
miglustat
evaluation of the transparency committee
miglustat
glycogen storage disease type ii
Cipaglucosidase Alfa
---
https://www.has-sante.fr/jcms/p_3456825/fr/pombiliti-cipaglucosidase-alfa-opfolda-miglustat-en-association-forme-tardive-maladie-de-pompe
2023
false
false
false
France
Cipaglucosidase Alfa
cipaglucosidase alfa
Glycogen storage disease type II late onset (disorder)
miglustat
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
miglustat
drug therapy, combination
glycogen storage disease type ii
---
